Perindopril

Cardiovascular disease is the leading cause of death worldwide. The long-term management of chronic diseases such as hypertension and heart failure is highly dependent on renin-angiotensin-aldosterone system (RAAS) inhibitors. As a third-generation angiotensin-converting enzyme inhibitor (ACEI), perindopril competitively blocks the conversion of angiotensin I to angiotensin II, an active substance that constricts blood vessels, and reduces the degradation of bradykinin, which not only lowers blood pressure steadily but also protects target organs such as the heart and kidneys. Clinically, in addition to being used alone or in combination to treat primary and secondary hypertension in patients of all ages, it can also be used for the long-term intervention of congestive heart failure and acute coronary syndrome to reduce the risk of recurrent cardiovascular events, and is a first-line drug recommended by hypertension guidelines in many countries.

At present, the global market size of perindopril API exceeds USD 320 million, and the compound annual growth rate from 2023 to 2029 is expected to remain at 4.7%. The core growth drivers are the increase in the penetration rate of hypertension medication at the primary care level and the standardized promotion of chronic disease management pathways for heart failure. In terms of the competitive landscape, after the patent of the original manufacturer expired, generic drugs have been rapidly launched in large volumes. China and India are the core global suppliers. There are more than 15 domestic enterprises whose oral preparations have passed the consistency evaluation. After the implementation of volume-based procurement, the demand of downstream preparation manufacturers for cost-effective and compliant APIs continues to rise. There is no publicly verifiable segmented data on the domestic API market share.

In response to the quality control and registration declaration needs of perindopril API, CATO provides a full set of impurity reference standards for this API. All products meet the requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, with complete structural confirmation and purity calibration data for the corresponding impurities. The core product specifications are kept in stable stock, which can fully support enterprises to meet the full-process needs of API R&D, quality consistency evaluation and routine testing after marketing.